Ameriprise reports 1.35M shares (5.4%) in Pasithea
Pasithea Therapeutics Corp Schedule 13G/A discloses ownership by Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC.
Rhea-AI Filing Summary
Pasithea Therapeutics Corp Schedule 13G/A discloses ownership by Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC. The filing reports 1,350,896 shares held with 5.4% of the class (CUSIP 70261F202). Ameriprise states CMIA’s holdings are included in AFI’s total and both entities disclaim beneficial ownership. The filing is signed by Michael G. Clarke and attaches exhibits identifying the acquiring subsidiary and a joint filing agreement.
Positive
- None.
Negative
- None.
Insights
Large passive holding reported: 1,350,896 shares (5.4%).
The Schedule 13G/A lists Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC as reporting persons for Pasithea Therapeutics Corp, showing shared voting and dispositive power over 1,350,896 shares. The filing follows passive-investor reporting conventions and includes a parent/affiliate attribution.
Key dependencies are the attribution language and exhibits identifying the subsidiary. Subsequent filings would show any changes; the current filing documents a static ownership snapshot as reported.
Key Figures
Key Terms
Schedule 13G/A regulatory
Beneficial Ownership regulatory
Joint Filing Agreement legal
FAQ
What stake does Ameriprise (KTTA) report in Pasithea Therapeutics?
Why are both Ameriprise Financial and CMIA listed on the Schedule 13G/A?
Does the filing indicate active trading or a passive position?
Who signed the Schedule 13G/A for Ameriprise and CMIA?
Are there exhibits attached to the filing and what do they show?
AI-generated analysis. How Rhea-AI works. Not financial advice.